Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 14/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410082 | 0.83 | CNR2 (0.38) | HCRTR2CNR2CD274PDCD1LG2CNR1 | |
| SCHEMBL27255850 | 0.77 | CD274 (0.38) | CD274PDCD1LG2PDCD1 | |
| SCHEMBL27887573 | 0.75 | POLB (0.44) | CNR2CD274PDCD1LG2 | |
| SCHEMBL19068348 | 0.75 | PDK2 (0.43) | CNR2CD274PDCD1LG2 | |
| SCHEMBL27887572 | 0.75 | HCRTR2 (0.34) | HCRTR2CNR2CNR1 | |
| SCHEMBL28714385 | 0.74 | — | — | |
| SCHEMBL2411441 | 0.74 | HTR1A (0.33) | CNR2CD274PDCD1LG2CNR1 | |
| SCHEMBL2276722 | 0.73 | HTR1A (0.40) | HTR2A | |
| SCHEMBL438335 | 0.73 | KEAP1 (0.37) | HCRTR2CD274PDCD1LG2 | |
| SCHEMBL2688403 | 0.73 | CD274 (0.34) | CD274PDCD1LG2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350010-B1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2350010-B1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8592457-B2 | Isonicotinamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| CN-102272103-A | Isonicotinamide orexin receptor antagonists | — | 2011-12-07 | — | — | CN | disclosed |
| US-20110201591-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-08-18 | — | — | US | disclosed |
| US-20110201591-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-08-18 | — | — | US | disclosed |
| US-20110201591-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-08-18 | — | — | US | disclosed |
| EP-2350010-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010051236-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051236-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201591-A1 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885CNR2 41/4885CD274 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.